Why the study?
Zinc supplementation trials have produced inconsistent outcomes in respiratory infections, prompting investigation into the role of zinc homeostasis in respiratory syncytial virus infection.
Zinc appears to be part of an interplay between RSV-induced oxidative stress and the host response to maintain redox balance, with zinc supplementation inhibiting RSV replication in vitro.
Preclinical zinc-RSV findings warrant no change in clinical practice; leaves open need for human trials to test supplementation.
Zinc deficiency rates in developing countries range from 20 to 30%, and zinc supplementation trials have been shown to correct clinical manifestations attributed to zinc deficiency, but the outcomes in the case of respiratory infections have been inconsistent. We aimed at understanding the role of zinc homeostasis in respiratory syncytial virus (RSV) infection. Infection of lung epithelial cell lines or primary small-airway epithelial cells led to an increase in labile zinc pools, which was due to increased uptake of zinc. Zinc supplementation inhibited RSV replication, whereas zinc chelation had an opposing effect, leading to increases in RSV titers. Increases in labile zinc in RSV-infected cells coincided with induction of reactive oxygen species (ROS). Both zinc depletion and addition of exogenous ROS led to enhanced RSV infection, whereas addition of the antioxidant inhibited RSV, suggesting that zinc is part of an interplay between RSV-induced oxidative stress and the host response to maintain redox balance.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: